BEAMing sheds light on drug resistance

Josh Lauring; Ben Ho Park

doi:10.1158/1078-0432.CCR-11-2556

BEAMing sheds light on drug resistance

Josh Lauring, Ben Ho Park

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

Targeted therapies against somatically altered genes are currently used for the treatment of many human cancers. The nascent technology known as BEAMing has the potential to increase the clinical utility of these agents because it allows for the detection of cancer mutations in peripheral blood, providing a rapid assessment of tumor mutation status.

Original language	English (US)
Pages (from-to)	7508-7510
Number of pages	3
Journal	Clinical Cancer Research
Volume	17
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-11-2556
State	Published - Dec 15 2011
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-11-2556

Cite this

@article{206556b198584967ad2a0dbe92c73655,

title = "BEAMing sheds light on drug resistance",

abstract = "Targeted therapies against somatically altered genes are currently used for the treatment of many human cancers. The nascent technology known as BEAMing has the potential to increase the clinical utility of these agents because it allows for the detection of cancer mutations in peripheral blood, providing a rapid assessment of tumor mutation status.",

author = "Josh Lauring and Park, {Ben Ho}",

year = "2011",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-11-2556",

language = "English (US)",

volume = "17",

pages = "7508--7510",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "24",

}

TY - JOUR

T1 - BEAMing sheds light on drug resistance

AU - Lauring, Josh

AU - Park, Ben Ho

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Targeted therapies against somatically altered genes are currently used for the treatment of many human cancers. The nascent technology known as BEAMing has the potential to increase the clinical utility of these agents because it allows for the detection of cancer mutations in peripheral blood, providing a rapid assessment of tumor mutation status.

AB - Targeted therapies against somatically altered genes are currently used for the treatment of many human cancers. The nascent technology known as BEAMing has the potential to increase the clinical utility of these agents because it allows for the detection of cancer mutations in peripheral blood, providing a rapid assessment of tumor mutation status.

UR - http://www.scopus.com/inward/record.url?scp=84055222120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055222120&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2556

DO - 10.1158/1078-0432.CCR-11-2556

M3 - Comment/debate

C2 - 22065078

AN - SCOPUS:84055222120

SN - 1078-0432

VL - 17

SP - 7508

EP - 7510

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 24

ER -

BEAMing sheds light on drug resistance

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this